A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction

Internal Medicine

Volumn 51, Issue 10, 2012, Pages 1187-1193

  Sunami, Eiko ^a   Usuda, Kazuhiro ^a   Nishiyama, Yutaka ^a   Otori, Tatuo ^a   Katsura, Kenichirou ^a   Katayama, Yasuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Depression; Fluvoxamine maleate; Ischemic stroke; Melatonin; Sleep disturbance

Indexed keywords

FLUVOXAMINE MALEATE; MELATONIN;

AGED; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; EMOTIONAL DISORDER; FEMALE; HUMAN; MALE; PITTSBURGH SLEEP QUALITY INDEX; SELF-RATING DEPRESSION SCALE; SLEEP DISORDER;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CEREBRAL INFARCTION; DEPRESSION; FEMALE; FLUVOXAMINE; HUMANS; MALE; MELATONIN; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS; STROKE;

EID: 84861738227     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6699     Document Type: Article

References (25)

1. Robinson RG, Bolduc PL, Price TR. Two-year longitudial study of poststroke mood disorders: diagnosis and outcome at one and two years. Stroke 18: 837-843, 1987.
2. Carod-Artal FJ. Post-stroke depression (ii): its differential diagnosis, complications and treatment. Rev Neurol 42: 238-244, 2006.
3. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1: 297-300, 1984.
4. Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, McDowell FH. Antidepressant therapy after stroke. A double blind trial. Arch Neurol 43: 763-765, 1986.
5. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31: 1829-1832, 2000.
6. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of poststroke depression: a three-month doubleblind placebo-controlled study with an open-label long-term follow up. J Neurol 250: 347-351, 2003.
7. Mendlewicz J, Linkowski P, Branchey L, Weinberg U, Weitzman ED, Branchey M. Abnormal 24 hour pattern of melatonin secretion in depression. Lancet 314: 1362, 1979.
8. Crasson M, Kjiri S, Colin A, et al. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 29: 1-12, 2004.
9. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects: an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 56: 123-127, 2000.
10. Carvalho LA, Gorenstein C, Moreno R, Pariante C, Markus RP. Effect of antidepressants on melatonin metabolite in depressed patients. J Psychopharmacol 23: 315-321, 2009.
11. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 12: 63-70, 1965.
12. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213, 1988.
13. Japan Stroke Association: Stroke Scale Committee. Japan Stroke Scale (Emotional Disturbance Scale) (JSSD·JSS-E). Nousotchu 25: 206-214, 2003 (in Japanese).
14. Japan Stroke Association: Stroke Scale Committee. Japan Stroke Scale (Motor Function) (JSS-M). Nousotchu 21: 353-356, 1999 (in Japanese).
15. Katayama Y, Usuda K, Nishiyama Y, Katsura K. Post-stroke depression. Nihon Ronen Igakukai Zashi 40: 127-129, 2003 (in Japanese, Abstract in English).
16. Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke 31: 1482-1486, 2000.
17. Uchiyama M. Melatonin treatment for circadian rhythm sleep disorder and insomnia. Suimin Iryou 2: 67-75, 2007 (in Japanese).
18. Rahman SA, Marcu S, Kayumov L, Shapiro CM. Altered sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors. Eur Arch Psychiatry Clin Neuro sci 260: 327-335, 2010.
19. Rahman SA, Kayumov L, Shapiro CM. Antidepressant action of melatonin in the treatment of Delayed Sleep Phase Syndrome. Sleep Med 11: 131-136, 2010.
20. Serfaty MA, Osborne D, Buszewicz MJ, Blizard R, Raven PW. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 25: 132-142, 2010.
21. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled trial. J Clin Psychopharmacol 30: 135-144, 2010.
22. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder. J Clin Psychiatry 71: 616-626, 2010.
23. Paffenbarger RS Jr, Kampert JB, Lee IM, Hyde RT, Leung RW, Wing AL. Changes in physical activity and other lifeway patterns influencing longevity. Med Sci Sports Exerc 26: 857-865, 1994.
24. Livingston G, Blizzard B, Mann A. Dose sleep disturbance predict depression in elderly people? A study in inner London. Br J GenPract 43: 445-448, 1993.
25. Foley DJ, Monjan AA, Izmirlian G, Hays JC, Blazer DG. Incidence and remission of insomnia among elderly adults in a biracial cohort. Sleep 22(Suppl 2): 373-378, 1999.